Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities

Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alp...

Full description

Saved in:
Bibliographic Details
Main Author: Abd Aziz, Noraini
Format: Thesis
Language:English
Published: 2013
Subjects:
Online Access:http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
id my-upm-ir.48690
record_format uketd_dc
spelling my-upm-ir.486902016-10-14T08:08:09Z Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities 2013-11 Abd Aziz, Noraini Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alpha subunit of hypoxia inducible factor 1 (HIF-1) is not degraded, the heterodimeric HIF-1 fails to transactivate target genes. HIF-1 and HIF-2 are related hypoxia-inducible transcription factors that are important for survival of hypoxic tumor cells. Most reports have focused on the effects of bortezomib on HIF-1 but not HIF-2 transcriptional activities. In the present study, the effect of bortezomib on HIF-2 activity in cells with different levels of expression of the HIF-1α and HIF-2α subunits, was investigated. Results showed that bortezomib treatment suppressed the transcription and expression of CA9, a HIF-1-specific target gene, but had minimal effects on EPO and GLUT-1, which are the target genes of both HIF-1 and HIF-2. A similar dichotomy of responses was also seen with exogenously-introduced hypoxia response elements of CA9 and EPO. These data led to a conclusion that bortezomib attenuates the transcriptional activity of only HIF-1 but not HIF-2. This novel finding on the lack of inhibitory effect of bortezomib on HIF-2 transcriptional activity will be important in the improvement of design and treatment modalities to enhance the efficacy of this and other proteasomal inhibitor drugs. Protease inhibitors - Therapeutic use Cancer - Chemotherapy 2013-11 Thesis http://psasir.upm.edu.my/id/eprint/48690/ http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf application/pdf en public masters Universiti Putra Malaysia Protease inhibitors - Therapeutic use Cancer - Chemotherapy
institution Universiti Putra Malaysia
collection PSAS Institutional Repository
language English
topic Protease inhibitors - Therapeutic use
Cancer - Chemotherapy

spellingShingle Protease inhibitors - Therapeutic use
Cancer - Chemotherapy

Abd Aziz, Noraini
Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
description Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alpha subunit of hypoxia inducible factor 1 (HIF-1) is not degraded, the heterodimeric HIF-1 fails to transactivate target genes. HIF-1 and HIF-2 are related hypoxia-inducible transcription factors that are important for survival of hypoxic tumor cells. Most reports have focused on the effects of bortezomib on HIF-1 but not HIF-2 transcriptional activities. In the present study, the effect of bortezomib on HIF-2 activity in cells with different levels of expression of the HIF-1α and HIF-2α subunits, was investigated. Results showed that bortezomib treatment suppressed the transcription and expression of CA9, a HIF-1-specific target gene, but had minimal effects on EPO and GLUT-1, which are the target genes of both HIF-1 and HIF-2. A similar dichotomy of responses was also seen with exogenously-introduced hypoxia response elements of CA9 and EPO. These data led to a conclusion that bortezomib attenuates the transcriptional activity of only HIF-1 but not HIF-2. This novel finding on the lack of inhibitory effect of bortezomib on HIF-2 transcriptional activity will be important in the improvement of design and treatment modalities to enhance the efficacy of this and other proteasomal inhibitor drugs.
format Thesis
qualification_level Master's degree
author Abd Aziz, Noraini
author_facet Abd Aziz, Noraini
author_sort Abd Aziz, Noraini
title Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_short Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_full Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_fullStr Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_full_unstemmed Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
title_sort effects of bortezomib on hif-1 and hif-2 transcriptional activities
granting_institution Universiti Putra Malaysia
publishDate 2013
url http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf
_version_ 1747811992592187392